Sanofi’s Efdoralprin Alfa Shows Superior Phase 2 Results in AATD
PARIS, France, May 18, 2026 Sanofi has announced positive Phase 2 ElevAATe trial results demonstrating that investigational therapy efdoralprin...
COPD
Advertisement
Altesa BioSciences Reports Positive Phase 2 Vapendavir Data in COPD
ORLANDO, Fla., May 19, 2026 Altesa BioSciences announced positive results from its randomized, placebo-controlled Phase 2 rhinovirus challenge study...
Transpire Bio Gains FDA Acceptance for High-Strength Generic Trelegy
SUNRISE, Fla., May 11, 2026 Transpire Bio Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
AstraZeneca Reports Phase III Success for Tozorakimab in COPD
CAMBRIDGE, United Kingdom, April 20, 2026 AstraZeneca has reported positive results from its pivotal Phase III MIRANDA trial, demonstrating...
Apogee Therapeutics Prices $350M Public Offering
SAN FRANCISCO & BOSTON, USA | March 24, 2026 Apogee Therapeutics, Inc. has successfully announced the pricing of its...
Advertisements
Harbour BioMed Reports Phase I Success for HBM9378 Antibody
Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...
CSA Medical Submits PMA for RejuvenAir After Pivotal Trial Success
BOSTON | January 7, 2026 — CSA Medical, a U.S.-based medical device company focused on interventional pulmonary therapies, has...
Advertisement
